Oneness Biotech Co Ltd develops botanical new drugs and several biological-active new chemical entities that are purified and molecularly modified from these botanical sources.

Announcement Of The Date Of The Company'S Board Of
Directors Meeting For The Thired Quarter Of 2024
Consolidated Financial Reports

A Us Patent Titled "Biomarkers For Lung Cancer Stem Cells"
Has Been Granted

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oneness Biotech (4743 TT)

Announcement Of The Date Of The Company'S Board Of Directors Meeting For The Thired Quarter Of 2024 Consolidated Financial Reports

A Us Patent Titled "Biomarkers For Lung Cancer Stem Cells" Has Been Granted

Oneness Biotech Co., Ltd. Receives A United States Patent Titled “Treating Ige-Mediated Allergic Diseases” On Fb825.

Oneness Has Received Medical Device Registration Approval On Bonvadis Topical Cream For Egypt

Oneness Announces The Information About The Investor'S Conference Of 2024 Q3.

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)